Redalpine, a pan-European venture capital firm headquartered in Zurich since 2006, has announced the close of a $250 million fund dedicated to early-stage investments in technology and science startups across the continent. The new vehicle, designated RAC VIII, represents a 25 percent increase over its predecessor, RAC VII, which raised $200 million in 2024.
The firm maintains offices in Zurich, Berlin, London and Silicon Valley and has previously backed notable European companies such as Mistral, N26, Basecamp Research and Proxima Fusion. RAC VIII will deploy capital in check sizes ranging from $1 million to $15 million, targeting between 15 and 20 portfolio companies while pursuing lead or co-lead positions in its investments.
Investment priorities for the new fund include robotics and artificial intelligence applications in drug discovery. Notably, half of Redalpine's investment team comprises scientists, reflecting the firm's emphasis on deep technical expertise. The previous fund's portfolio is nearly 50 percent concentrated in UK-based ventures, which have collectively raised more than $1.1 billion in subsequent funding rounds.
AI is levelling the playing field more than ever. The advantage now lies with whoever understands the underlying science and the hardest problems best, and that has always been Europe's strength.
Sebastian Becker, general partner at Redalpine
We're seeing a new generation of highly ambitious founders who are determined to build and scale world-leading tech companies from here and establish Europe as a global technology power.
Sebastian Becker, general partner at Redalpine
Source: Tech.eu
